Beni Morgenstern
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Beni Morgenstern has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Carlos Pastorino
Universidade de São Paulo, Brasil
3 shared publications - Mayra de Barros Dorna
Children’s Institute, Faculty of Medicine of the University of São Paulo 15 , São Paulo
3 shared publications - Ana Paula Beltran Moschione Castro
Division of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, São Paulo, Brazil
2 shared publications - Nayara Maria Furquim Nasser
Faculdade de Medicina, Universidade de São Paulo (HC-FMUSP), Instituto da Criança e do Adolescente, Departamento de Pediatria, Divisão de Alergia e Imunologia, Hospital das Clínicas, São Paulo, SP, Brazil
2 shared publications - Aidé Tamara Staines-Boone
Departamento de Inmunología Pediátrica, Instituto Mexicano del Seguro Social Unidad Médica de Alta Especialidad N°25, Monterrey, México
1 shared publication - Alejandra King
Universidad de Chile 41 Facultad de Medicina Santiago
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 24
Insights from long-term follow-up of patients treated with oral immunotherapy for cow's milk allergy
- 13 August 2026
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 24
Open AccessInsights from long-term follow-up of patients treated with oral immunotherapy for cow's milk allergy
- Open Access
- 6 October 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (4)
Clinical features, genotypes, and geographic distribution of 238 Latin American CGD patients
Chronic granulomatous disease (CGD) is an inborn error of immunity (IEI) caused by mutations in genes encoding components of the NADPH oxidase complex, leading to defective microbial killing and increased susceptibility to infections. This study analyzed clinical, genetic, and geospatial data from 238 CGD patients across eight Latin American countries. Genetic variants were identified in 141 patients (59%), with XL-CGD being the most common form (77%). Pneumonia (80%), lymphadenopathy (63%), and skin infections (55.5%) were frequent, with bacteria and fungi, such as Staphylococcus aureus, Aspergillus spp., and mycobacteria, as major pathogens. Antimicrobial prophylaxis was widely used, while IFN-γ was mainly prescribed in Mexico, mainly in cases of classic CGD (XL-CGD). Hematopoietic stem cell transplantation (HSCT) did not improve survival compared to prophylaxis. The leading cause of death was infection, particularly pneumonia and sepsis. XL-CGD patients had worse survival outcomes. The study highlights the need for improved genetic diagnosis, newborn screening, regional treatment guidelines, and expanded access to HSCT.
- 6 October 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (4)
Open AccessClinical features, genotypes, and geographic distribution of 238 Latin American CGD patients
Chronic granulomatous disease (CGD) is an inborn error of immunity (IEI) caused by mutations in genes encoding components of the NADPH oxidase complex, leading to defective microbial killing and increased susceptibility to infections. This study analyzed clinical, genetic, and geospatial data from 238 CGD patients across eight Latin American countries. Genetic variants were identified in 141 patients (59%), with XL-CGD being the most common form (77%). Pneumonia (80%), lymphadenopathy (63%), and skin infections (55.5%) were frequent, with bacteria and fungi, such as Staphylococcus aureus, Aspergillus spp., and mycobacteria, as major pathogens. Antimicrobial prophylaxis was widely used, while IFN-γ was mainly prescribed in Mexico, mainly in cases of classic CGD (XL-CGD). Hematopoietic stem cell transplantation (HSCT) did not improve survival compared to prophylaxis. The leading cause of death was infection, particularly pneumonia and sepsis. XL-CGD patients had worse survival outcomes. The study highlights the need for improved genetic diagnosis, newborn screening, regional treatment guidelines, and expanded access to HSCT.
- Open Access
- 10 April 2025
- Published by Elsevier in Jornal de Pediatria
- Vol. 101 (4) , 569-575
Understanding the natural history of selective IgA deficiency
- 10 April 2025
- Published by Elsevier in Jornal de Pediatria
- Vol. 101 (4) , 569-575
Open AccessUnderstanding the natural history of selective IgA deficiency